Nektar (NKTR) Therapeutics announced a new collaboration agreement to evaluate Nektar’s rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus. Rezpegaldesleukin is a ...

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports.

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) on February 14 and set a price target of $4.00. The company’s shares closed ...